Prof. Paul Monagle MBBS(Monash), MD(Monash), MSc (Health Research Methodology- McMaster). FRACP, FRCPA, FCCP is a past Stevenson Chair and Head of Department of Paediatrics, University of Melbourne (2008-2016); Head Department Pathology, University of Melbourne (2005-2008); Director of Laboratory Services Royal Children’s Hospital Melbourne(2000-2005), Head of Clinical Haematology(1998-2010), Acting Head of Children’s Cancer Centre Royal Children’s Hospital (RCH)(2010-2012). Currently, Paul is Professor Paediatrics, University of Melbourne, Clinical Haematologist Sydney Children’s Hospital and RCH, and Co Group leader Haematology research, Murdoch Children’s Research Institute.
Paul is a past chair of the paediatric/perinatal Scientific Subcommittee of ISTH; leader paediatric chapter of the ACCP antithrombotic guidelines for over a decade; member of the NIH working party into thrombotic disorders in paediatric cardiology patients; member of the ASH venous thrombosis guideline steering committee, and chair of the paediatric panel; Co-author of multiple textbooks; 40 chapters in major international textbooks; over 350 publications, with over 10000 citations. He has supervised 15 PhD students to completion, and has been involved in education, advocacy and fund raising at multiple levels locally, nationally and internationally.
Paul was a member of federal QUPC (Quality use in pathology committee) (2007-2017) and served on the boards of Murdoch Children’s Research Institute and Royal Children’s Hospital Foundation for many years. A member of CCOPMM (Consultative Council of Obstetric and Paediatric Morbidity and Mortality) (2008-2021), and chaired the child and adolescent subcommittee(2015-2021). CCOPMM is a statutory body that reviews all maternal, neonatal, and child deaths in Victoria and reports directly to the health minister. A current member of the ASH haemostasis and thrombosis working group and the ISTH guidelines and guidance committees.
Major research interests include the natural history and diagnosis of VTE in children, the pharmacology of anticoagulants in children, clinical trials of anticoagulants, optimal use of laboratory monitoring of anticoagulants in children, developmental haemostasis and coagulation biology, developing normative laboratory data, and anticoagulation in the setting of artificial circuits. Thus his highly collaborative research methodologies have included discovery and development of patents; basic science including structure function relationships of coagulation proteins; translational clinical and laboratory research; Clinical Trials including being PI of the Fontan A study, the first major RCT of anticoagulation in children with congenital heart disease, a major role in the Einstein studies of rivaroxaban in children and being on the steering committee for the paediatric apixaban primary prophylaxis trial. Quantitative and Qualitative research including tool development, validation and modification; and finally evidence based literature analysis and guideline or policy development. Since 2020 a major focus has been COVID related research including cell culture mechanistic studies, clinical biomarker and monitoring studies, in addition to clinical trial development.